Gurley Amelia L, Lacocque Jeremy, Mercer Mary P, Mason Michael, Wiebers Jenni, Lara Vanessa, Silverman Eric C, Brown John F, Graterol Joseph, Gunn Elaina, Middleton Mikaela T, Herring Andrew A, Hern H Gene
Department of Emergency Medicine, University of California San Francisco, San Francisco, California.
San Francisco Fire Department, San Francisco, California.
Prehosp Emerg Care. 2025;29(4):435-440. doi: 10.1080/10903127.2024.2449512. Epub 2025 Jan 23.
Opioid use disorder (OUD) remains a common cause of overdose and mortality in the United States. Emergency medical services (EMS) clinicians often interact with patients with OUD, including during or shortly after an overdose. The aim of this study was to describe the characteristics and outcomes of patients receiving prehospital buprenorphine for the treatment of opioid withdrawal in an urban EMS system.
We performed a retrospective chart review of all initial cases of administration of buprenorphine-naloxone from April 2023 to July 2024 during the first 16 months of a program involving prehospital EMS administration of buprenorphine-naloxone by EMS clinicians to patients with OUD experiencing acute opioid withdrawal in San Francisco. The primary outcome involved reduction in Clinical Opioid Withdrawal Score (COWS) and other adverse events including worsened withdrawal (or increased COWS), nausea, patient destination, and loss to follow up were also assessed.
Buprenorphine was administered to 131 patients. In 82 (62.6%) cases, patients presented in withdrawal after receiving naloxone from bystanders or EMS as a treatment for overdose. The average COWS prior to administration was 16.1 ± 6.5 and the median COWS prior to administration was 15 (IQR: 11-19). Of the 78 cases where a COWS was available, 74 (94.9%) experienced symptom improvement, with the median COWS dropping from 15 (IQR: 11-19) to 7 (IQR: 4-13) between first and last recorded values. No adverse effects were reported in prehospital records. There was one reported in-hospital incident of withdrawal in the Emergency Department presumably precipitated by buprenorphine. Data on outcomes after EMS transport were limited. Only six patients were successfully contacted at 30 day follow up, but five of these patients were in long-term OUD treatment programs, and three reported sustained abstinence from opioid use. During case review, we found two cases where physicians assisted EMS personnel in recognizing recent methadone use, but no other missed exclusion criteria requiring physician input.
In San Francisco, prehospital administration of buprenorphine for acute opioid withdrawal by EMS clinicians resulted in symptomatic improvement, and case review suggests administration can be safe without direct EMS physician oversight.
在美国,阿片类药物使用障碍(OUD)仍然是过量用药和死亡的常见原因。紧急医疗服务(EMS)临床医生经常与患有OUD的患者互动,包括在过量用药期间或之后不久。本研究的目的是描述在城市EMS系统中接受院前丁丙诺啡治疗阿片类药物戒断的患者的特征和结局。
我们对2023年4月至2024年7月期间在旧金山一项涉及EMS临床医生对患有急性阿片类药物戒断的OUD患者进行院前丁丙诺啡 - 纳洛酮给药的项目的前16个月内所有丁丙诺啡 - 纳洛酮初始给药病例进行了回顾性病历审查。主要结局包括临床阿片类药物戒断评分(COWS)的降低,还评估了其他不良事件,包括戒断症状加重(或COWS增加)、恶心、患者去向以及失访情况。
131名患者接受了丁丙诺啡治疗。在82例(62.6%)病例中,患者在从旁观者或EMS接受纳洛酮作为过量用药治疗后出现戒断症状。给药前的平均COWS为16.1±6.5,给药前的中位数COWS为15(四分位间距:11 - 19)。在有COWS记录的78例病例中,74例(94.9%)症状得到改善,首次和最后记录值之间的中位数COWS从15(四分位间距:11 - 19)降至7(四分位间距:4 - 13)。院前记录中未报告不良反应。急诊科有1例据推测由丁丙诺啡引发的院内戒断事件报告。关于EMS转运后的结局数据有限。在30天随访时仅成功联系到6名患者,但其中5名患者参加了长期OUD治疗项目,3名报告持续戒除阿片类药物使用。在病例审查过程中,我们发现2例医生协助EMS人员识别近期美沙酮使用情况的案例,但未发现其他需要医生干预的遗漏排除标准。
在旧金山,EMS临床医生对急性阿片类药物戒断进行院前丁丙诺啡给药可使症状改善,病例审查表明在没有EMS医生直接监督的情况下给药可能是安全的。